tiprankstipranks
Trending News
More News >
Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
Singapore Market
Advertisement

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) AI Stock Analysis

Compare
6 Followers

Top Page

SG:9G2

Singapore Institute of Advanced Medicine Holdings Ltd.

(SGX:9G2)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
S$0.00
▼(-100.00% Downside)
The overall stock score is primarily influenced by financial performance challenges, including high leverage and negative profitability. Technical analysis provides some stability, but valuation concerns due to a negative P/E ratio and lack of dividend yield weigh on the score.

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) vs. iShares MSCI Singapore ETF (EWS)

Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model

Company DescriptionSingapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.
How the Company Makes MoneyThe company generates revenue primarily through its healthcare services, which include diagnostic imaging, radiotherapy, and oncology treatment. These services are offered to patients directly or through partnerships with hospitals and clinics. Revenue is also derived from collaborations with medical research institutions and healthcare providers, through which the company offers its specialized expertise and advanced technological solutions. The company's earnings are significantly bolstered by its strategic partnerships with technology providers, allowing them to access and implement the latest medical technologies, which attract more patients and healthcare partners. Additionally, they may receive funding or grants from governmental or private healthcare initiatives aimed at enhancing cancer treatment capabilities in the region.

Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview

Summary
The company shows strong revenue growth but faces significant profitability challenges with negative net profit and EBIT margins. High leverage and negative returns on equity pose financial risks, despite improvements in free cash flow.
Income Statement
30
Negative
The company exhibits a strong revenue growth rate of 95.43% in the latest period, indicating a positive trajectory in sales. However, profitability remains a significant concern with negative net profit margins (-166.53%) and EBIT margins (-146.29%), suggesting operational inefficiencies and high costs relative to revenue.
Balance Sheet
40
Negative
The balance sheet shows a high debt-to-equity ratio of 1.05, indicating significant leverage which could pose financial risks. The return on equity is negative (-47.02%), reflecting poor profitability and returns for shareholders. The equity ratio stands at 44.61%, showing a moderate level of equity financing.
Cash Flow
35
Negative
The cash flow statement reveals a substantial free cash flow growth rate of 91.31%, which is a positive sign. However, the operating cash flow to net income ratio is negative (-0.62), indicating that the company is not generating sufficient cash from operations to cover its net losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue15.71M15.71M16.65M16.23M13.81M12.92M
Gross Profit-8.52M14.42M15.36M-2.60M-4.31M-2.32M
EBITDA-11.04M-11.08M-13.42M-10.78M-8.02M-3.06M
Net Income-26.16M-26.16M-37.45M-18.07M-12.43M-9.35M
Balance Sheet
Total Assets124.71M124.71M138.76M159.52M174.36M172.08M
Cash, Cash Equivalents and Short-Term Investments2.84M2.84M3.16M11.05M15.84M10.29M
Total Debt58.21M58.21M46.10M80.77M87.30M92.26M
Total Liabilities69.07M69.07M57.01M114.60M120.31M112.90M
Stockholders Equity55.64M55.64M81.74M44.93M54.05M59.18M
Cash Flow
Free Cash Flow-11.08M-10.78M-14.80M-19.89M-11.26M-9.72M
Operating Cash Flow-10.93M-10.63M-14.26M-5.45M-7.15M-4.26M
Investing Cash Flow112.97K113.13K-263.72K-1.45M3.72M-5.25M
Financing Cash Flow10.50M10.20M6.64M2.11M9.18M10.66M

Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.03
Positive
100DMA
0.03
Positive
200DMA
0.04
Positive
Market Momentum
MACD
<0.01
Positive
RSI
54.46
Neutral
STOCH
38.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.46 is Neutral, neither overbought nor oversold. The STOCH value of 38.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:9G2.

Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
65
Neutral
S$1.88B29.156.20%2.50%8.90%4.57%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
-39.37%-5.63%30.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.04
-0.04
-50.00%
SG:BSL
Raffles Medical Group
1.00
0.12
13.25%

Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events

Singapore Institute of Advanced Medicine Streamlines Decision-Making Process
Aug 8, 2025

The Singapore Institute of Advanced Medicine Holdings Ltd. has dissolved its Strategic Review Committee (SRC) as of August 8, 2025. The Board of Directors will now directly handle the functions and recommendations previously managed by the SRC to streamline decision-making and expedite the implementation of initiatives.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 18, 2025